New antibiotic beats superbugs at their own game

Jul 03, 2008
Ceftobiprole Effective Against VRSA
Strains of bacteria that are resistant to the antibiotic vancomycin grow easily in its presence (top), but are completely eliminated (bottom) when exposed to Ceftobiprole. Credit: The Rockefeller University

The problem with antibiotics is that, eventually, bacteria outsmart them and become resistant. But by targeting the gene that confers such resistance, a new drug may be able to finally outwit them. Rockefeller University scientists tested the new drug, called Ceftobiprole, against some of the deadliest strains of multidrug-resistant Staphylococcus aureus (MRSA) bacteria, which are responsible for the great majority of staphylococcal infections worldwide, both in hospitals and in the community.

The research, to be published in the August 2008 issue of the journal Antimicrobial Agents and Chemotherapy and available online now, looked at how well Ceftobiprole worked against bacterial clones that had already developed resistance to other drugs. In every case, Ceftobiprole won. "It just knocked out the cells 100 percent," says the study's lead investigator, Alexander Tomasz, head of the Laboratory of Microbiology at Rockefeller.

Previous research had already shown that -- in general -- Ceftobiprole was highly effective against most clinical isolates of S. aureus. "Instead, we looked more carefully at the highly resistant cells that already occur in such clinical isolates at very low frequency -- maybe in one bacterium in every 1,000," says Tomasz. Ceftobiprole was able to kill these resistant cells.

Never before has an antibiotic been tested this way. "In the history of antibiotic development, an antibiotic arrives on the scene, and sooner or later resistant bacteria emerge," Tomasz says. "We sought to test in advance which would win this particular chess game: the new drug, or the bacteria that now cause human deaths."

In an ominous new "move" in this chess game, S. aureus strains with resistance to vancomycin (VRSA), a different class of antibiotics, also began to appear in hospitals in the United States. Ceftobiprole was also able to kill these new resistant VRSA strains.

The drug is effective because the chemists who developed Ceftobiprole managed to outwit the bacteria at their own game, Tomasz says. The broad-spectrum antibiotic was discovered by Basilea Pharmaceuticals, based in Basel, Switzerland, and is being developed in the U.S. and worldwide by Johnson & Johnson. The research was supported by Johnson & Johnson along with a grant from the U.S. Public Health Service.

Source: Rockefeller University

Explore further: Prion trials and tribulations: Finding the right tools and experimental models

Related Stories

Light echo helps researchers map out parts of galaxy

2 hours ago

Thousands of years before humans invented agriculture, a bright burst of X-rays left the dense neutron star Circinus X-1, located in the faint Southern constellation Circinus. A year and a half ago, those ...

Cuban, US scientists bond over big sharks

3 hours ago

Somewhere in the North Atlantic right now, a longfin mako shark—a cousin of the storied great white—is cruising around, oblivious to the yellow satellite tag on its dorsal fin.

Gimmicks and technology: California learns to save water

3 hours ago

Billboards and TV commercials, living room visits, guess-your-water-use booths, and awards for water stinginess—a wealthy swath of Orange County that once had one of the worst records for water conservation ...

Recommended for you

Researchers reveal a genetic blueprint for cartilage

Jul 02, 2015

Cartilage does a lot more than determine the shapes of people's ears and noses. It also enables people to breathe and to form healthy bones—two processes essential to life. In a study published in Cell Re ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

menkaur
not rated yet Jul 03, 2008
beat - no
open new fighting front - yes
but it's a remarkable achievement

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.